David Moskowitz
Principal @ 8VC
San Francisco Bay Area, United States
David Moskowitz is a Series A investor at 8VC in San Francisco Bay Area focused on Biotechnology and Life Science. David is a Principal at 8VC where he focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data and thecharacterization of epigenetic changes associated with aging in T cells.Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease.Mr. Moskowitz graduated from Stanford University, Stanford University School of Medicine, and Brown University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries David Moskowitz invests in
Stages David Moskowitz invests in
Countries David Moskowitz invests in
Investment Focus
Industry
- Biotechnology 5 (56%)
- Life Science 4 (44%)
- Health Care 2 (22%)
- Pharmaceutical 2 (22%)
- Machine Learning 2 (22%)
Stage
- Series A 5 (56%)
- Seed 1 (11%)
- Series B 1 (11%)
- Series C 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ushur
|
Ushur is a cloud-based automation platform that automates service workflows in both the backend process and conversational interfaces.The company develops intelligent automation solutions that include, Ushur Virtual Customer Assistant, smart technology that automates proactive member, claimant, agent, or broker communications across virtually anychannel, reaching out to customers, understanding what they need, and automatically taking the next steps; Ushur SmartMail, a software that allows insurers to process high-volumes of the customer, agent and broker email automatically, allowing carriers to respond faster and efficiently; Ushur Flowbuilder, the web-based no-code builder allows claims, broker services, and customer support teams to build, deploy and track rich digital engagements that improve business agility and the customer experience while minimizing the burden on IT. By leveraging the company's Robotic Process Automation (RPA) and Language Intelligence Service Architecture (LISA), insurance companies can accelerating capital and time-intensive processes like claims, customer support, billing, and enrollment to digitally transform service workflows. | $50M / Series C / Feb 07, 2023 | |
Mantra Bio
|
Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at awide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity. | $9M / Series A / Jan 04, 2023 | |
Cartography Biosciences
|
Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets. | $57M / Series A / Jul 19, 2022 | |
hC Bioscience
|
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome. | $24M / Series A / Feb 23, 2022 | |
Appia Bio
|
Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies. It works on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized forAllogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs). | $52M / Series A / May 11, 2021 | |
Model Medicines
|
Model Medicines uses human expertise and AI to accelerate the development of life-changing drugs at scale. Model Medicines harnesses AI and ML with its ActivPred AI Drug Discovery Platform to discover drugs that may be repositioned to serve as therapeutics to treat patients suffering from humankind’s toughest diseases.The drugs that ModelMedicines discovers can enter clinical trials in as little as several months. | $4.1M / Seed / Feb 01, 2021 | |
|
Ushur
|
Ushur is a cloud-based automation platform that automates service workflows in both the backend process and conversational interfaces.The company develops intelligent automation solutions that include, Ushur Virtual Customer Assistant, smart technology that automates proactive member, claimant, agent, or broker communications across virtually anychannel, reaching out to customers, understanding what they need, and automatically taking the next steps; Ushur SmartMail, a software that allows insurers to process high-volumes of the customer, agent and broker email automatically, allowing carriers to respond faster and efficiently; Ushur Flowbuilder, the web-based no-code builder allows claims, broker services, and customer support teams to build, deploy and track rich digital engagements that improve business agility and the customer experience while minimizing the burden on IT. By leveraging the company's Robotic Process Automation (RPA) and Language Intelligence Service Architecture (LISA), insurance companies can accelerating capital and time-intensive processes like claims, customer support, billing, and enrollment to digitally transform service workflows. | $25M / Series B / Nov 05, 2020 | |
|
Mantra Bio
|
Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at awide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity. | $25M / Series A / Jul 29, 2020 | |
|
Ushur
|
Ushur is a cloud-based automation platform that automates service workflows in both the backend process and conversational interfaces.The company develops intelligent automation solutions that include, Ushur Virtual Customer Assistant, smart technology that automates proactive member, claimant, agent, or broker communications across virtually anychannel, reaching out to customers, understanding what they need, and automatically taking the next steps; Ushur SmartMail, a software that allows insurers to process high-volumes of the customer, agent and broker email automatically, allowing carriers to respond faster and efficiently; Ushur Flowbuilder, the web-based no-code builder allows claims, broker services, and customer support teams to build, deploy and track rich digital engagements that improve business agility and the customer experience while minimizing the burden on IT. By leveraging the company's Robotic Process Automation (RPA) and Language Intelligence Service Architecture (LISA), insurance companies can accelerating capital and time-intensive processes like claims, customer support, billing, and enrollment to digitally transform service workflows. | $12M / Series A |
Co-Investors
Aflac Global Ventures
2 deals together
Allen & Company
2 deals together
BoxGroup
2 deals together
Gaingels
2 deals together
Third Point Ventures
2 deals together
Viking Global Investors
2 deals together
About 8VC
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
8VC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Kolicich
Founding Partner
|
|||
|
David Moskowitz
Principal
|
|||
Jack Moshkovich
Principal
|
|||
Sebastian Ruales
EIR
|
|||
Alex Moore
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Moskowitz invest in?
David Moskowitz invests primarily in Biotechnology, Life Science and Health Care startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David Moskowitz last invest?
The most recent investment recorded for David Moskowitz closed in Feb 2023. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
